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Abstract
Introduction—Structural changes in the heart are known risk factors for atrial fibrillation (AF). 
An association between cardiac troponin T (hs-cTnT), a marker of myocardial cell damage 
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measured with a high sensitivity assay, and the risk of AF could have implications for AF risk 
stratification.
Objective—To estimate the association between hs-cTnT and the risk of incident AF in the 
Atherosclerosis Risk in Communities (ARIC) Study, a prospective cohort of middle-aged adults 
from 4 U.S. communities.
Methods—Study included 10,584 participants (mean age 62.7 years) free of AF in 1996-98 and 
followed through 2008. AF was defined using ICD codes from hospitalizations and death 
certificates. Participants with undetectable hs-cTnT levels (58%) were assigned the lower limit of 
measurement (5 ng/L). Net reclassification improvement (NRI) was used to examine the 
discriminative ability of hs-cTnT for 10-year AF risk prediction (categories: <5%, 5-15%, and 
>15%).
Results—A total of 920 incident AF cases were observed over 109,227 person-years. After 
adjustment, a 1-standard deviation difference in ln(hs-cTnT) was associated with a hazard ratio 
(HR) of 1.16 (95% CI=1.10-1.23). Compared with those with undetectable levels, participants 
with hs-cTnT ≥14 ng/L had a HR of 1.78 (95% CI=1.43-2.24). Addition of hs-cTnT to known AF 
predictors did not increase the c-statistic appreciably (0.756 vs 0.758) or improve risk stratification 
(NRI=0.4%, 95% CI=−1.4%-2.3%).
Conclusions—Hs-cTnT level is associated with an increased incidence rate of AF but did not 
improve risk stratification.
INTRODUCTION
Although substantial information exists regarding risk factors for atrial fibrillation (AF)(1), 
the predictive ability of these risk factors is modest (2;3). With recent evidence suggesting 
that myocardial ischemia may play a mechanistic role in AF development (4), and our 
established understanding of the role of processes associated with myocardial damage such 
as myocardial infarction (MI) or heart failure (HF) in its development, the assessment of 
subclinical myocardial damage may facilitate risk stratification for AF.
Previous clinical and population-based studies have found that high-sensitivity cardiac 
troponin T (hs-cTnT), a marker of subclinical myocardial damage, is associated with an 
increased risk of structural heart disease (5), incident HF (6), cardiovascular mortality (6), 
silent brain infarcts (7), and all-cause mortality (5). However, the association between hs-
cTnT and the risk of incident AF remains unknown, as does the role of hs-cTnT in risk 
prediction and stratification for incident AF. Our primary objective was therefore to estimate 
the association between hs-cTnT and the risk of incident AF in participants of the 
Atherosclerosis Risk in Communities (ARIC) study. Our secondary objectives were to 
determine if this association differs by sex or race and to examine the predictive ability of 
hs-cTnT for incident AF.
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The association between hs-cTnT and the risk of incident AF was examined using a 
longitudinal analysis of ARIC, a prospective study of the etiology of atherosclerosis in 4 
U.S. communities (Forsyth County, North Carolina; Jackson, Mississippi; Washington 
County, Maryland; and Minneapolis, Minnesota)(8). ARIC involved 15,792 participants 
aged 45-64 years at the time of enrollment (1987-1989). Hs-cTnT levels were assayed in 
2009-2010 from plasma samples collected at ARIC visit 4, conducted in 1996-98 and stored 
at −70°C; this visit served as the baseline for the present study.
Exclusion criteria included evidence of a history of AF at visit 4 (from study ECGs or prior 
hospital discharge codes from baseline up to visit 4)(n=298), a missing or unreadable visit 4 
electrocardiogram (n=174), and missing data for hs-cTnT (n=378) or covariates (n=153). 
Few participants from Minneapolis, MN or Washington County reported a race other than 
Caucasian and few from all sites reported a race other than Caucasian or African American 
(n=69). These individuals were excluded to avoid sparse strata and to appropriately adjust/
stratify by race and study center. Thus, the final study population consisted of 10,584 
participants.
Exposure Assessment
The hs-cTnT assays used in ARIC have been described previously (9). Briefly, using plasma 
samples from ARIC visit 4, hs-cTnT levels were measured using Elecsys Troponin T (lot 
number 154102, Roche Diagnostics, Indianapolis, IN), a high-sensitivity assay implemented 
on an automated Cobas e411 analyzer. All samples with undetectable hs-cTnT levels were 
assigned a value of 5 ng/L, the lower limit of detection. Analysis of 418 masked duplicate 
ARIC samples revealed a reliability coefficient of 0.98 (10). Participants were classified into 
one of four hscTnT categories: ≤ 5 ng/L (i.e., undetectable levels), 6-8 ng/L, 9-13 ng/L, and 
>14 ng/L. Similar categorization has been used previously in studies of hs-cTnT and other 
cardiovascular endpoints (9).
Outcome Measurement
Incident AF was defined using previously described methods (11;12). Briefly, possible 
hospitalizations were assessed during annual telephone follow-ups and review of local 
hospital discharge lists. Hospital discharge ICD codes and dates were abstracted, as 
previously described (13). Participants were considered to have AF if they had an ICD-9 
code for AF (ICD-9 code 427.31) or atrial flutter (ICD-9 code 427.32) or if AF was listed on 
the death certificate (ICD-9 code 427.3 or ICD-10 code 148). Hospitalizations with an ICD 
code indicating that the AF occurred in hospital and those with ICD codes for cardiac 
procedures, including heart revascularization surgery or other cardiac surgery involving 
valves or septa were not considered events. The date of incident AF was defined as the date 
of the first evidence of its occurrence, and only 1 event was considered per participant. A 
previous ARIC sub-study has shown that the positive predictive value of ICD-9 codes for 
AF is ~ 90% (12).
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First, the dose-effect association between hs-cTnT and incident AF was explored modeling 
the natural log of hs-cTnT with a restricted cubic spline. There was some mild nonlinearity 
in the top 2.5% of the distribution, and sensitivity analyses were conducted excluding these 
individuals to obtain conservative estimates. These analyses removed this non-linearity; both 
analyses resulted in similar effect estimates and only those using the entire ln(hs-cTnT)/SD 
distribution are reported here. Using Poisson regression, crude and age-, sex-, and race-
adjusted incidence rates of AF were calculated for each hs-cTnT category.
Our primary analysis involved 3 Cox proportional hazards models to examine the 
association between hs-cTnT categories and the time to incident AF with varying degree of 
covariate adjustment. The first model was minimally adjusted, including only age, sex, and 
race. The second model also adjusted for AF risk factors included in the augmented Cohorts 
for Heart and Aging Research in Genomic Epidemiology (CHARGE) AF consortium risk 
score (2), including height, body mass index, systolic blood pressure, diastolic blood 
pressure, current smoking, diabetes, prevalent HF, previous MI, ECG-derived left 
ventricular hypertrophy, PR interval <120 ms, PR interval >199 ms, and use of anti-
hypertensive medications. The third model included further adjustment for study center, 
education ≥ high school graduate, current alcohol intake, creatinine level, high-sensitivity C-
reactive protein (hsCRP) level, and N-terminal pro b-type natriuretic peptide (NT-proBNP) 
level. In sensitivity analyses, analyses were restricted to participants free of prevalent 
coronary heart disease (CHD) and HF at baseline, with CHD and HF defined using 
previously published criteria (13;14). In additional analyses, time-dependent adjustment for 
incident MI and HF using hospitalization data collected during annual follow-ups was 
included to examine its role as a potential mediator; incident MIs included only those 
reviewed and adjudicated by the Endpoints Committee. Sex and race were examined as 
potential effect modifiers. In sensitivity analyses, hs-cTnT was modeled continuously as a 
one standard deviation change on the ln(hs-cTnT) scale (SD=0.47).
The predictive ability of hs-cTnT for incident AF was examined in a two-step procedure. 
First, the c-statistic for the Cox proportional hazards models (15) was computed with and 
without the addition of hs-cTnT to traditional AF risk factors. Second, the net 
reclassification improvement (NRI)(16) was calculated and reclassification tables used (17) 
to examine the number of participants whose predicted 10-year AF risk was reclassified by 
adding hs-cTnT to previously-identified risk factors. NRI was examined with risk of AF 
treated categorically using cutoffs (<5%, 5-15%, or >15%)(3), and hs-cTnT treated log-
linearly (16). In additional analyses, given the arbitrary nature of such categorization, NRI 
was examined using a continuous (or category-free) approach (16;18).
We conducted several sensitivity analyses. First, to examine the impact of death as a 
competing risk, we used the Fine and Gray method. Second, for illustrative purposes, we 
repeated our NRI analyses with NT-proBNP, a biomarker with higher granularity than hs-
cTnT that has been shown to improve AF risk prediction in the CHARGE-AF Consortium 
of community-based cohort studies (including ARIC)(19), as the exposure variable.
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Competing risk analyses were conducted using R version 3.0.2 (R Core Team, Vienna, 
Austria); all other analyses were conducted using SAS version 9.3 (The SAS Institute, Cary, 
NC).
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RESULTS
Demographic and Clinical Characteristics
There were a number of important differences in the demographic and clinical 
characteristics between hs-cTnT groups (Table 1). Participants with higher hs-cTnT levels 
were more likely to be older, more likely to be male, and more likely to be African 
American. Participants with higher hs-cTnT levels also had a higher prevalence of most 
cardiovascular risk factors, CVD, and current use of cardiac medications but lower 
prevalences of smoking and alcohol use.
Hs-cTnT and the Incidence Rate of AF
Overall, the crude incidence rate of AF was 8.4 per 1,000 person-years (95% CI=7.9-9.0). 
The rate ranged from 5.5 per 1,000 person-years (95% CI=4.9-6.1) among participants with 
undetectable hs-cTnT levels to 23.6 per 1,000 person-years (95% CI=20.4-27.3) among 
participants with hs-cTnT ≥14 ng/L (p for trend <0.0001)(Table 2). Similar trends were 
observed in both sex- and race-defined subgroups (Online Appendix 1).
After adjustment for known risk factors, a one-SD increase in ln(hs-cTnT) was associated 
with an increased rate of incident AF (HR=1.16, 95% CI=1.10-1.23)(Figure 1; Online 
Appendices 2-3). This association persisted after excluding participants with prevalent CHD 
or HF and following time-dependent adjustment for incident MI and HF.
The association between hs-cTnT as a categorical variable and the rate of incident AF was 
also estimated (Table 3). After adjusting for known risk factors, the rate of incident AF 
increased across hs-cTnT categories (p for trend <0.0001), with participants in the highest 
hscTnT category having a HR=1.78 (95% CI=1.43-2.24) compared with participants with 
undetectable levels. Similar results were obtained when restricting to participants free of 
CHD or HF at baseline. Although attenuated, a clinically important increased rate remained 
present after adjustment for incident MI and HF.
The association between hs-cTnT as a continuous variable and the rate of incident AF was 
present in both men and women, with a slightly stronger association in women (p for 
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interaction=0.03)(Online Appendix 3). This interaction persisted after restricting analyses to 
participants free of CHD and HF at baseline (p=0.02) but not after adjustment for incident 
MI and HF (p=0.22). This interaction with sex was not present when examining hs-cTnT 
categorically (p=0.15)(Figure 2). There was no evidence of interaction between hs-cTnT and 
race (p=0.18).
Discriminative Ability of hs-cTnT
The addition of ln(hs-cTnT) as a continuous variable to a model containing known AF risk 
factors did not increase the c-statistic appreciably, both overall (0.756 vs 0.758) and in 
sexand race-defined subgroups (Online Appendix 4). Similar c-statistics were observed in 
men and women, and African Americans had a slightly higher c-statistic than Caucasians. 
Similar results were obtained when examining hs-cTnT categorically.
Risk Reclassification
The addition of hs-cTnT to previously-identified AF predictors did not improve risk 
classification (NRI =0.4%; 95% CI=−1.4-2.3%)(Table 4). When using the continuous 
approach, the inclusion of hs-cTnT did not result in significant reclassification (NRI=−7.3%, 
95% CI=−14.5%-0.030%).
Sensitivity Analyses
Our sensitivity analyses that considered death as a competing risk produced results that were 
consistent with those of our primary analyses (HR for ln(hs-cTnT)/SD=1.08, 95% 
CI=1.01-1.15; categorical hs-cTnT: HR for 6-8 ng/L: 1.21 (95% CI=1.00-1.45), 9-13 ng/L: 
1.39 (95% CI=1.14-1.69), ≥14 ng/L: 1.45 (95% CI=1.15-1.83). In addition, we found that 
unlike hs-cTnT, the addition of NT-proBNP to known risk factors improved risk 
classification (Online Appendix 5).
DISCUSSION
We aimed to examine the association between hs-cTnT level and the risk of incident AF. 
We found that the risk of AF increased with increasing hs-cTnT level and this association 
was consistent across different sex and race groups. However, the addition of hs-cTnT to 
traditional risk factors did not improve risk prediction, nor did it improve risk stratification. 
Similar results were obtained for both categorical and continuous NRI analyses. These 
results suggest that, although there is a strong and consistent association between hs-cTnT 
and incident AF, the clinical utility of hs-cTnT is modest at best. With no improvements in 
discrimination or prediction, findings are insufficient to recommend the use of hs-cTnT for 
AF risk stratification.
While hs-cTnT may not improve risk stratification for incident AF, its clinical relevance 
requires further investigation. If a biomarker such as hs-cTnT is related to a particular 
pathophysiology (e.g., ischemia or fibrosis), it may still be clinically useful to guide 
therapies that could prevent AF. Finally, biomarkers such as hs-cTnT may allow for the 
identification of groups which have a differential response to preventative therapies or may 
be altered by such therapies and thus be a surrogate for efficacy.
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Previous studies have examined the association between troponin levels and clinical 
outcomes among patients with AF. These studies have shown that hs-cTnT level is 
associated with poorer outcomes in this population (20;21). Recently, investigators in the 
Heart and Soul Study showed that higher hs-cTnT levels are associated with a decreased left 
atrial function index in participants with stable CHD, which may have implications for the 
development of AF (22).
Previous studies have also found that hs-cTnT level is associated with prevalent AF. Using 
data from the Uppsala Longitudinal Study of Adult Men, Eggers and colleagues examined 
cross-sectionally the association between hs-cTnT and cardiovascular risk factor levels and 
prevalent cardiovascular diseases (23). Although the authors found that hs-cTnT level was 
associated with previous or prevalent AF, they did not examine incident AF as part of their 
longitudinal analysis.
To our knowledge, the association between hs-cTnT and incident AF has only been 
examined in one previous study. Anegawa and colleagues (24) examined this association 
among 220 individuals free of CVD who were enrolled during routine check-ups in Uku, 
Japan. A total of 12 incident AF cases were identified by electrocardiogram; these 
individuals had a substantially higher hs-cTnT level than those without AF (0.0115 ± 0.0052 
ng/mL vs 0.0058 ± 0.0061 ng/mL, p=0.002). After adjustment for potential confounders, 
ln(hs-cTnT) was associated with an increased rate of AF (HR=4.81, 95% CI=1.41-16.37). 
This observed association is consistent with the findings of the present study, though our 
larger sample size has allowed for the estimation of more precise estimates in a biracial 
cohort of men and women. Importantly, while similar results have been observed between 
troponin I and AF risk (25), to our knowledge, the predictive ability of hs-cTnT for incident 
AF has not been examined previously.
The strengths of our study merit a brief mention. First, detailed medical histories were 
obtained and cardiovascular risk factor levels were measured in ARIC, allowing for rigorous 
adjustment for known AF risk factors and minimizing residual confounding. Second, hs-
cTnT level was measured using a validated assay that, in a sub-sample of ARIC participants, 
has been shown to have a reliability coefficient of 0.98 (9). Finally, the incorporation of risk 
reclassification analyses allows for the evaluation of the clinical utility of hs-cTnT for AF 
risk prediction.
Our study also has some potential limitations. First, since the baseline for this study was 
ARIC visit 4, follow-up was restricted to 1996-98 to 2008. With 920 incident AF cases, the 
study has ample power to address its primary objective but the power to examine 
interactions may be modest. Second, although events were assessed using a previously-
validated definition (12), asymptomatic cases and those managed in outpatient settings were 
not included as events. This misclassification is not expected to be associated with 
participants’ hs-cTnT level and thus should be non-differential and bias towards the null 
hypothesis. Third, despite rigorous statistical adjustment, some residual confounding due to 
unmeasured variables (e.g., sleep apnea, physical activity) remains possible. Finally, ARIC 
is a cohort of middle age Caucasian and African American participants from only a few 
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geographic regions, and the generalizability of our results outside this demographic is not 
known.
CONCLUSIONS
Higher hs-cTnT level is strongly associated with an increased rate of incident AF. This 
association is independent of previously-identified AF risk factors and incident MI and HF. 
However, hs-cTnT did not improve our predictive ability or risk stratification for AF relative 
to previously-identified AF risk factors. These results do not support the use of hs-cTnT for 
risk stratification as part of routine clinical practice.
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Age-, sex-, and race-adjusted Cox proportional hazards model with restricted cubic splines 
examining the association between ln(high-sensitivity cardiac troponin T) and the risk of 
incident atrial fibrillation. Knots were placed at the 75th, 90th, and 95th percentiles. Hazard 
ratios were estimated for a 1-standard deviation change (SD=0.47) in ln(high-sensitivity 
cardiac troponin T). The top 2.5% of the high-sensitivity cardiac troponin T distribution was 
excluded from this analysis due to some mild non-linearity. Abbreviation: SD=standard 
deviation.
Filion et al. Page 10














Adjusted hazards ratios and corresponding 95% confidence intervals for sex- and race-
specific models examining the association between high-sensitivity cardiac troponin T and 
the risk of incident atrial fibrillation. Models were adjusted for variables included in Model 
3 (see Table 3).
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Table 4
Predicted 10-Year Risk of Incident Atrial Fibrillation with and without High-Sensitivity Cardiac Troponin T 
among Participants of the ARIC Study (1996-1998 to 2008)
*,†
.
Traditional Risk Factors + High-Sensitivity Cardiac Troponin T
Traditional Risk Factors Only < 5% 5% to 15% >15% Total
Participants with AF, n (%)
    <5% 132 (91.7) 12 (8.3) 0 (0) 144 (18.7)
    5% to 15% 6 (1.9) 294 (94.2) 12 (3.9) 312 (40.5)
    >15% 0 (0) 19 (6.0) 296 (94.0) 315 (40.8)
    Total, n (%) 138 (17.8) 325 (42.2) 308 (40.0) 771 (100)
Participants without AF, n (%)
    <5% 4,723 (96.6) 164 (3.4) 0 (0) 4,887 (49.8)
    5% to 15% 163 (4.3) 3,545 (93.5) 84 (2.2) 3,792 (38.6)
    >15% 0 (0) 129 (11.4) 1,005 (88.6) 1,134 (11.6)
    Total, n (%) 4,886 (49.8) 3,838 (39.1) 1,089 (11.1) 9,813 (100)
Abbreviations: AF: Atrial fibrillation
*
Percentages sum to 100 across rows except the marginal cells, which represent the percentage of all participants with and without AF. Risks were 
estimated using Kaplan-Meier methods to account for observations that were censored within 10 years.
†
See model 3 in Table 3 for a list of traditional risk factors for atrial fibrillation included in this analysis. Atrial fibrillation risk cutoffs were 
developed in the Framingham Heart Study (3).
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